You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

557 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Document
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pentostatin (Unfunded),
alemtuzumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021
Guidelines and Advice
Status: Current
Jun 2021
Document
Jun 2021
Document
Jun 2021

Pages